Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report
Abstract
ABSTRACT Background Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options. Recent drug developments of cefiderocol (FDC) and sulbactam-durlobactam (SUD) provide novel treatment options for XDR A. baumannii. Case Summary We present the case of a patient with XDR A. baumannii bacteremia following a prolonged hospital course for gangrenous cholecystitis and hospital-acquired bacterial pneumonia. He completed a 14-day course of FDC and SUD with clinical resolution and was discharged home. Conclusion This case demonstrates the potential efficacy of FDC combined with SUD in treating XDR A. baumannii bacteremia, highlighting the need for further research into combination therapy regimens for XDR A. baumannii.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.